| 15.92 -0.1 (-0.62%) | 10-24 14:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.75 | 1-year : | 25.4 |
| Resists | First : | 18.62 | Second : | 21.75 |
| Pivot price | 17.47 |
|||
| Supports | First : | 13.57 | Second : | 11.29 |
| MAs | MA(5) : | 16.15 |
MA(20) : | 17.14  |
| MA(100) : | 17.23 |
MA(250) : | 8.06 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 13.2 |
D(3) : | 13.7 |
| RSI | RSI(14): 47.7 |
|||
| 52-week | High : | 83.59 | Low : | 0.09 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RGC ] has closed above bottom band by 21.3%. Bollinger Bands are 71.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 65 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 16.42 - 16.53 | 16.53 - 16.63 |
| Low: | 14.94 - 15.08 | 15.08 - 15.2 |
| Close: | 15.81 - 16.02 | 16.02 - 16.22 |
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Tue, 07 Oct 2025
Regencell Goes From Collapse to Comeback: RGC Stock Targets $30 After $20 Break - FXLeaders
Tue, 07 Oct 2025
No-Revenue Biotech Soars 64,000% – Is Regencell (RGC) a Breakthrough or a Bubble? - ts2.tech
Tue, 07 Oct 2025
Regencell Bioscience (NASDAQ:RGC) Shares Gap Up - Here's Why - MarketBeat
Sun, 05 Oct 2025
Regencell Bioscience Holdings (RGC) Is Up 13.2% After Index Addition and Positive Trial Results—Has the Story Changed? - simplywall.st
Mon, 11 Aug 2025
Regencell Bioscience Holdings (RGC) Stock Analysis: Exploring the Volatility and Growth Potential - DirectorsTalk Interviews
Mon, 07 Jul 2025
Regencell Bioscience Stock Volatility Continues Monday - Investopedia
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 494 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 96.1 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 1,530 (K) |
| Shares Short P.Month | 1,900 (K) |
| EPS | -0.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.7 % |
| Return on Equity (ttm) | -47.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1603.5 |
| PEG Ratio | 0 |
| Price to Book value | 1603.5 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|